Pear Therapeutics Inc. obtained FDA approval for Somryst, the first prescription digital therapeutic for chronic insomnia. The app provides structured cognitive behavior therapy (CBT) with clinical dashboards for physicians. While CBT is the recommended first-line therapy for insomnia, the U.S. has only 500 therapists certified to provide CBT for insomnia (CBTi) for the estimated 30 million Americans who suffer from chronic difficulty going to and staying asleep.
Keeping you up to date on recent developments in neurology, including: Using AI for neonatal brain image segmentation; New imaging method sheds light on AD; Investigation of inherited mutations in ASD.
Despite seeing good growth in 2019, with net sales jumping to almost $2.4 million vs. $993,000 over the previous year, Electrocore Inc. has suspended its guidance due to uncertainty over COVID-19. The company previously said full-year revenue should be in the range of $7 million to $9 million.
Keeping you up to date on recent developments in neurology, including: ‘Natural killer’ cells could halt PD progression; Neuroinflammation linked to several forms of dementia; GOF, LOF mutations take different paths to same result; Study links GABA, mitochondria, social defects.
Jerusalem-based Brainsway Ltd. had good news to report with the presentation of positive data from a multicenter study evaluating its deep transcranial magnetic stimulation (dTMS) system as an aid in smoking cessation.
Keeping you up to date on recent developments in neurology, including: Neuexcell Therapeutics sees promise for gene therapy for HD; VR shows promise for early detection of MS balance problems; New findings increase understanding of anorexia nervosa; Study: Surgery with anesthesia not linked to indicator of Alzheimer's.
TORONTO – If Toronto’s Sunnybrook Hospital and the W. Garfield Weston Foundation get their way, a CA$33 million (US$24 million) initiative unveiled March 2 dramatically will increase patient access to made-to-measure ultrasound technology for penetrating the blood-brain barrier to treat Alzheimer's disease and brain cancer.
Keystone Heart Ltd., of Caesarea, Israel and Tampa, Fla., scored a win in Europe after obtaining the CE mark for the Triguard 3 cerebral embolic protection (CEP) device. It is designed to minimize the risk of cerebral damage by deflecting embolic debris away from cerebral circulation during transcatheter aortic valve implantation (TAVI) and other transcatheter heart procedures. According to the company, the device is the only product with a CE mark designed to cover and protect all three major cerebral aortic arch vessels.
Tirat Carmel, Israel-based Insightec Ltd. has inked a deal for a series F financing of up to $150 million led by Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries. The round, which has a post-money valuation of $1.3 billion, is earmarked for continued study of the company’s low-intensity, focused ultrasound technology in treating certain movement disorders.
Keeping you up to date on recent developments in neurology, including: Seismic imaging technology could deliver finely detailed images of the human brain; Scientists monitor brains replaying memories in real time; Drug shows promise in reducing deadly brain swelling after stroke.
RSS
